Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. May 28, 2014; 20(20): 6262-6278
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6262
Table 7 Treatment endpoints in clinical use
TreatmentDescription
BiochemicalNormalization of serum ALT
Virological
HBeAg-positiveLoss of HBeAg, Anti-HBe antibodies, serum HBV-DNA < 2000 IU/mL
HBeAg-negativeSerum HBV-DNA < 2000 IU/mL
CompleteBiochemical and virological response with loss of serum HBsAg
HistologicalDecrease in necroinflammatory activity without worsening in fibrosis